J&J's PALMAZ-SCHATZ STENT SHOWS CONTINUED RESTENOSIS REDUCTION
This article was originally published in The Gray Sheet
Executive Summary
J&J's PALMAZ-SCHATZ STENT SHOWS CONTINUED RESTENOSIS REDUCTION compared to balloon angioplasty in one-year follow-up results from the Stent Restenosis (STRESS) study. Of the 205 patients randomized for treatment via Johnson & Johnson Interventional Systems' Palmaz-Schatz stent implantation, 10.2% required target lesion revascularization (coronary artery bypass surgery or repeat angioplasty) within one year. This figure compared to an 18.4% rate in the 202-patient group receiving percutaneous transluminal coronary angioplasty. The STRESS researchers said that the continued trend of fewer events in the stent group is "concordant with the reduced restenosis rates" associated with stenting.